OZYMF.US Orphazyme A/S

Healthcare Biotechnology USA Stocks
90.00 USD
Close of Nov 17, 2026
90.00 90.00
Market cap
USD 4.84M
P/E
-
P/B
0.35x
ROE
21.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is OZYMF.US undervalued?

Graham number

The Graham number of Orphazyme A/S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orphazyme A/S fundamental analysis

No fundamental analysis for Orphazyme A/S yet.

Orphazyme A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orphazyme A/S

Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.

Full company profile